Genomic and transcriptomic data reveal molecular differences between homologous recombination deficiency subgroups in Chinese ovarian cancer patients
This study identified distinct molecular and immune profiles between HRD subgroups in Chinese ovarian cancer patients. Patients with HRD-high and STAT1 expression ≥ 74 suggests PARPi benefit.
Authors
- Wenhao Zhou (ORCID: https://orcid.org/0000-0001-8956-7238)
- Lanlan Zhao (ORCID: https://orcid.org/0000-0001-8280-443X)
- Fenghua Zhang (ORCID: https://orcid.org/0009-0003-6051-1646)
- Jingde Jia
- Haitao Luo (ORCID: https://orcid.org/0000-0001-8865-6466)
- Kaiyun Qin
- Wenhong Zhao
- Hongxia Wang (ORCID: https://orcid.org/0000-0003-3481-6940)
- Yu Yu
- Na Wang (ORCID: https://orcid.org/0000-0001-9196-7978)
- Jiaqian Wang (ORCID: https://orcid.org/0000-0002-6189-2810)
- Congcong Song
- Xu Cui
- Yijie Li (ORCID: https://orcid.org/0000-0001-7551-117X)
- Zhengmao Zhang (ORCID: https://orcid.org/0000-0003-4461-4154)
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Hebei General Hospital (CN)
Publication Details
- Journal
- Human Genomics
- Published
- 2025-08-31
- DOI
- https://doi.org/10.1186/s40246-025-00806-w
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Natural Science Foundation of Hebei Province
- Horizon 2020 Framework Programme